Sold as Gabitril. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 16, 2026, FDA lists 5 applications for Tiagabine Hydrochloride (sold as Gabitril), first approved Sep 30, 1997, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Tiagabine HCl | Part D | $5.8M | -8% | 2,199 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Treating Schizophrenia by Correcting Abnormal Brain DevelopmentSchizophrenia · Beth Israel Deaconess Medical Center | Phase 3 | Active, not recruiting | Sep 16, 2005 |
| Sep 30, 1997 | GabitrilNDA 20646 · New molecular entity | Cephalon | 19 | Marketed |
| Nov 4, 2011 | Tiagabine HydrochlorideANDA 77555 | Sun Pharm Inds | 0 | Discontinued |
| Oct 13, 2017 | Tiagabine HydrochlorideANDA 206857 | Wilshire Pharms Inc | 0 | Discontinued |
| Dec 8, 2017 | Tiagabine HydrochlorideANDA 208181 | Amneal Pharms Co | 0 | Discontinued |
| Nov 16, 2021 | Tiagabine HydrochlorideANDA 214816 | Msn | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA